Myriad Genetics has dropped one of its development programs for an experimental therapy--MPC-7869--after it failed to perform better than a placebo in a clinical trial for prostate cancer. Myriad researchers say they will continue to study the drug as a therapy for Alzheimer's. They added that the drug was well tolerated in an elderly population. Report